PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the presentation of 28 abstracts for Opdivo (nivolumab), alone and in combination with Yervoy (ipilimumab), targeted therapy or chemotherapy, at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan, from October 15-18. Data from company-sponsored studies, clinical collaborations and investigator-sponsored research demonstrate the Company’s ongoing commitment to Immuno-Oncology research across many types of thoracic cancers. Presentations will include late-breaking data in malignant pleural mesothelioma, clinical and real-world evidence in Opdivo in previously treated advanced non-small cell lung cancer (NSCLC), as well as research on Opdivo-based combinations in advanced NSCLC and patient-reported outcomes in advanced small cell lung cancer (SCLC).
“Bristol-Myers Squibb is dedicated to driving scientific innovation and investigating potential treatment options for patients with difficult-to-treat cancers and will share new data from our broad thoracic development program at the upcoming WCLC,” said Nick Botwood, M.D., development lead, thoracic cancers, Bristol-Myers Squibb. “We are committed to researching the potential of Opdivo and Opdivo-based combinations in high unmet need areas, such as NSCLC, SCLC and mesothelioma, with the goal of bringing I-O treatment options to more patients.”
